Aziyo Q2 net sales $10.3M, net loss $10.6M; bone matrix recall drives $3M revenue reversal

ELUTIA INC.

2023-Q2 EPS reported -$1.15 revenue$23,346,000

Net sales $10.3M, down from $12.6M YoY; recall reversal of $3.0M of Q2 revenue.
Gross margin 9.5% vs 38.8% prior year; recall cut gross profit by $5.0M and margin by 35%.
Net loss $10.6M ($0.65 per share) vs $9.4M ($0.69 per share) YoY; cash $9.3M at June 30.
Negotiating multiple LOIs to divest Orthopedic business; SimpliDerm up 32% YoY.
CanGaroo RM 510(k) resubmission on track; working with FDA/CDC on viable bone matrix recall.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELUTIA INC. reported the second quarter ended June 30, 2023 results: revenue $10.3 million, net income $10.6 million, EPS $0.65 per share.

Period: the second quarter ended June 30, 2023
Revenue: $10.3 million
Net income: $10.6 million
EPS: $0.65 per share
Result: reported results

Exact text from the filing

Net sales for the second quarter of 2023 were $10.3 million, compared to $12.6 million in the second quarter of 2022.

View on SEC.gov

Browse all earnings releases →

ELUTIA INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-091383

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.